Potassium
Also sold as: Potassium salts · Potassium chloride · Potassium citrate · Dietary potassium
An essential electrolyte for nerve, muscle and cardiac function. Dietary and salt-substitution evidence is stronger than evidence for routine potassium capsules in people with normal potassium status.
Longevity Energy
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Energy: No energy or cramp-prevention benefit is established in potassium-replete people; correcting documented hypokalemia is a separate medical indication.
- Longevity: Potassium-enriched salt reduced deaths and cardiovascular events in high-risk adults; it also reduced sodium, so this is not proof that isolated capsules extend life.
REALITY CHECK // Potassium-rich salt replacement reduced events in high-risk adults but also lowered sodium, so a capsule cannot claim that entire effect. Bananas or tablets are not established cramp prevention in people with normal status. The source extraction incorrectly placed AI intake values in UL fields; those values are not safety ceilings.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No classical EFSA/US UL is established for healthy adults in this dossier. EFSA 3500 mg/day and US adult adequate intakes around 2600-3400 mg/day are nutritional AI values, not upper limits or supplement targets. A 99 mg tablet is not a universal legal maximum or an individualized safety threshold; specific product/jurisdiction rules need verification.
Summary
Potassium supplementation lowers blood pressure chiefly in hypertension, while potassium-enriched salt replacement has hard-outcome evidence in high-risk adults. Neither supports indiscriminate high-dose capsules. Citrate has a separate stone-prevention role. Kidney function and potassium-retaining medicines determine safety; hyperkalemia can cause fatal arrhythmias.
Mechanism
Potassium maintains membrane potentials and neuromuscular excitability. Renal excretion and aldosterone regulate balance. Citrate and bicarbonate also provide alkali; citrate increases urinary citrate/pH, so its stone effect is not interchangeable with chloride replenishment.
Typical studied dose
A blood-pressure meta-analysis reported a subgroup total intake of 90-120 mmol/day; this is not a standalone capsule prescription. The large salt-substitution trial used approximately 25% KCl salt replacing ordinary salt, combining more potassium with less sodium. The dossier does not supply exact form-specific supplement trial ranges; calculator trial comparisons remain unavailable.
Upper limit
No classical EFSA/US UL is established for healthy adults in this dossier. EFSA 3500 mg/day and US adult adequate intakes around 2600-3400 mg/day are nutritional AI values, not upper limits or supplement targets. A 99 mg tablet is not a universal legal maximum or an individualized safety threshold; specific product/jurisdiction rules need verification.
Popular stacks with Potassium
Not enough stack data yet. A combination with Potassium appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Potassium chloride (KCl), approximately 52% elemental potassium Best for: Clinician-guided replacement when chloride depletion is relevant. |
Unstandardized: active content unknown | no comparable trial range | Highly soluble; carrier identity matters when chloride has also been lost. Solid formulations can cause irritation/ulceration, especially with GI disease or large doses. |
Studied standard [REFERENCE // CHECK_PREPARATION] 52% is the dossier rounded chemical composition, not absorption. Exact trial dose range is unavailable, so automatic efficacy comparison is disabled. |
| Potassium citrate, dossier approximation 38% elemental potassium Best for: Clinician-directed recurrent calcium-stone prevention when appropriate. |
Unstandardized: active content unknown | no comparable trial range | Absorbable alkalinizing salt; urinary citrate/pH effects distinguish it from KCl. GI tolerance can differ; safety still depends on kidney function and medicines. |
Good option [GOOD // CHECK_PREPARATION] Confirm exact salt/hydration and elemental declaration. Rounded dossier fraction is not a universal formulation conversion; no invented therapeutic mg target. |
| Potassium bicarbonate, approximately 39% elemental potassium Best for: Recognizing an alkalinizing preparation rather than assuming all salts are equivalent. |
Unstandardized: active content unknown | no comparable trial range | Alkalinizing salt studied mainly for bone/acid-base surrogate outcomes. Can cause bloating or gas. |
Caution [CAUTION // CHECK_PREPARATION] 39% is rounded composition; no demonstrated fracture benefit or supplied exact trial range. |
| Potassium gluconate, approximately 17% elemental potassium Best for: Checking a low-dose OTC product label. |
Unstandardized: active content unknown | no comparable trial range | Low elemental fraction means compound mass differs substantially from labelled potassium mass. Generally considered GI-tolerable, but hyperkalemia risk is unchanged by the carrier. |
Caution [CAUTION // CHECK_PREPARATION] Use the actual elemental declaration; do not compensate by taking many tablets to reach an AI. Trial comparison unavailable. |
Common label traps
- TRAP_01 // 3500 mg is a safe supplement upper limit
3500 mg/day is an EFSA adequate intake, not a UL. Total dietary intake and prescribed supplementation are distinct. - TRAP_02 // 99 mg tablets prove all larger doses are illegal or safe below 99 mg
Common low-dose products reflect formulation/regulatory history; 99 mg is not a universal legal cap or safety guarantee. Individual risk depends on kidneys, medicines and the product. - TRAP_03 // More potassium always means lower blood pressure
Effects are nonlinear and concentrate in hypertension/high sodium. Excess can be dangerous with renal impairment or potassium-retaining drugs. - TRAP_04 // Citrate is best for every potassium problem
Citrate addresses urinary citrate/alkali needs; KCl may be appropriate in chloride loss. Form choice depends on the clinical context. - TRAP_05 // Bananas prevent every cramp
No supporting cramp-prevention RCT in potassium-replete people is indexed here; this gap differs from medically documented hypokalemia.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- Blood pressure Strong · benefit
A 22-RCT meta-analysis (n=1606) reported SBP -3.49 mmHg (95% CI for reduction 1.82-5.15) and DBP -1.96 mmHg (0.86-3.06), with benefit concentrated in hypertension and not normotension. A 90-120 mmol/day intake subgroup showed SBP -7.16 mmHg (1.91-12.41). A 32-RCT dose-response synthesis supports a nonlinear relationship, not unlimited benefit.
PMID 23558164 PMID 32500831 - Cardiovascular events: salt substitution Strong · benefit
A cluster RCT in roughly 21,000 high-risk adults in rural China found fewer strokes, major cardiovascular events and deaths with approximately 25% KCl salt substitution. Sodium reduction and potassium increase were coupled; kidney/hyperkalemia-risk exclusions limit applicability. Exact rate ratios are not extracted here.
PMID 34459569 PMID 36196475 PMID 38379029 - Recurrent calcium kidney stones Moderate · benefit
Cochrane RCT synthesis found reduced recurrent calcium stones with citrate salts, including potassium citrate. This is salt-specific clinical treatment with limited/moderate-quality comparisons, not a general potassium-capsule claim.
PMID 26439475 - Bone surrogates versus fractures Limited · benefit
Alkaline potassium salts lowered resorption markers/calcium excretion, but a causal assessment did not establish dietary acid load as a cause of bone disease. Fracture prevention is unproven.
PMID 25572045 PMID 21529374 - Diabetes risk: observational Limited · benefit
Prospective-study meta-analyses associate higher potassium intake/status with lower diabetes risk; dietary and health confounding prevent a causal supplement-prevention claim.
PMID 36432472 PMID 37788131 - Mortality and stroke: dietary associations Limited · benefit
Cohort syntheses link higher potassium/lower sodium-to-potassium ratio with lower mortality or stroke risk. These are associations, distinct from the coupled salt-substitution RCT.
PMID 38519925 PMID 29907351 PMID 27792643 - Cramp prevention and energy without deficiency No established evidence
No supporting RCT is indexed in this dossier for potassium-replete people. This is an evidence gap, not a cited negative trial; documented hypokalemia requires medical treatment.
Reader questions
Why does a tablet contain 99 mg when intake guidance is in grams?
AI figures concern overall dietary intake. Common 99 mg tablets are not intended to supply the entire daily intake, and that number is not a universal legal cap or safety threshold. Do not take many tablets to meet an AI.
Is an accidental double dose dangerous?
Risk depends on the actual elemental dose, kidney function, medicines and symptoms. Do not infer safety from the tablet count; seek clinical/poison advice for a suspected significant overdose, symptoms or high-risk conditions.
Can I correct a low blood potassium result myself?
A low result needs cause assessment and laboratory-guided correction, including magnesium and medication review. The right salt and amount cannot be selected from a general card.
Will citrate prevent stones for everyone?
Evidence concerns selected adults with recurrent calcium stones and urinary chemistry needs. It is not interchangeable with KCl or suitable for unsupervised use in kidney disease.
Stack interactions
- Caution ACE inhibitors, ARBs and potassium-sparing diuretics [CAUTION // CLINICAL_REVIEW]
Potassium retention plus a supplement can trigger severe hyperkalemia and arrhythmia; use only with clinician/laboratory oversight.
PMID 24762462 - Caution Trimetoprim, NSAIDs, calcineurin inhibitors and drospirenone [CAUTION // CLINICAL_REVIEW]
These can raise potassium or impair excretion; medication review is particularly important with renal disease. - Caution Magnesium depletion [CAUTION // CLINICAL_REVIEW]
Low magnesium can perpetuate renal potassium loss and hinder correction. This is clinical electrolyte management, not a reason to self-dose both minerals. - Caution Sodium intake [CONTEXT // COINTERVENTION]
The strongest event trial changed both sodium and potassium through salt replacement; lower sodium is part of the intervention.
PMID 34459569 PMID 38379029
Red flags: interactions and who should avoid it
Interactions
ACE inhibitors, ARBs, spironolactone/eplerenone/amiloride, trimethoprim, NSAIDs, calcineurin inhibitors and drospirenone can increase potassium or its retention. Supplementation may cause dangerous hyperkalemia, particularly with kidney impairment. SGLT2-inhibitor evidence suggests lower hyperkalemia risk, not an additive toxicity warning. Low magnesium can impair potassium correction; sodium intake affects BP response.
Avoid or ask a doctor first if
Known hyperkalemia, CKD/dialysis, adrenal insufficiency or potassium-retaining medicines require clinician management. GI strictures/ulcer disease raise concern with solid KCl, which can injure the gut. Pregnancy high-dose supplementation, arrhythmias, refeeding and eating-disorder electrolyte disturbances need individual care. Weakness, tingling, palpitations or suspected overdose need prompt assessment; symptoms cannot reliably exclude hyperkalemia.
Sources (PubMed, 11)
- Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses.
PMID 23558164 · 2013 · systematic review and meta-analysisBlood-pressure RCT meta-analysis with hypertension-dependent effects and extracted numerical estimates.
- Effect of Salt Substitution on Cardiovascular Events and Death.
PMID 34459569 · 2021 · randomized controlled trialHigh-risk cluster RCT of coupled lower-sodium/higher-potassium salt replacement and hard cardiovascular outcomes.
- Effectiveness of salt substitute on cardiovascular outcomes: A systematic review and meta-analysis.
PMID 36196475 · 2022 · systematic review and meta-analysisMeta-analysis of cardiovascular outcomes with salt substitutes.
- Citrate salts for preventing and treating calcium containing kidney stones in adults.
PMID 26439475 · 2015 · systematic review and meta-analysisCochrane synthesis of citrate salts for recurrent calcium stones, not all potassium forms.
- The effect of supplementation with alkaline potassium salts on bone metabolism: a meta-analysis.
PMID 25572045 · 2015 · systematic review and meta-analysisAlkaline-potassium bone-metabolism surrogate effects.
- Causal assessment of dietary acid load and bone disease: a systematic review & meta-analysis applying Hill's epidemiologic criteria for causality.
PMID 21529374 · 2011 · systematic review and meta-analysisCounterweight: causal assessment does not establish dietary acid load as a cause of bone disease.
- Dietary Potassium Intake and Risk of Diabetes: A Systematic Review and Meta-Analysis of Prospective Studies.
PMID 36432472 · 2022 · systematic review and meta-analysisProspective observational association between potassium intake and diabetes risk.
- Sex-specific associations between sodium and potassium intake and overall and cause-specific mortality: a large prospective U.S. cohort study, systematic review, and updated meta-analysis of cohort studies.
PMID 38519925 · 2024 · systematic review and meta-analysisDietary sodium/potassium associations with mortality; observational inference.
- Bioavailability of Magnesium and Potassium Salts Used as Potential Substitutes for Sodium Chloride in Human Nutrition - A Review.
PMID 40931546 · 2025 · narrative reviewReview of potassium salt bioavailability/formulation considerations.
- Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management.
PMID 24762462 · 2014 · narrative reviewClinical risks and management of hyperkalemia.
- The contribution of sodium reduction and potassium increase to the blood pressure lowering observed in the Salt Substitute and Stroke Study.
PMID 38379029 · 2024 · randomized controlled trialSeparates contributions to blood-pressure effects in salt substitution; the parent intervention changed both nutrients.
Community comments
No approved comments yet. Comments are held for moderation.